GSTM4 Suppresses Prostate Cancer Progression by Targeting TRIM27‐mediated ACLY Ubiquitination and Lipid Metabolism
Kang‐Ping Xiong, Fei Liu, Wang Wang, Gang Wang, Kai‐Yu Qian, Sheng Tu, Si‐Ming Chen, Hui‐Min Xu, Shan‐Shan Zhang, Yong Li, Xing‐Huan Wang, Hong Weng · 2026
Read GSTM4 Suppresses Prostate Cancer Progression by Targeting TRIM27‐mediated ACLY Ubiquitination and Lipid Metabolism by Kang‐Ping Xiong, Fei Liu, Wang Wang, Gang Wang, Kai‐Yu Qian, Sheng Tu, Si‐Ming Chen, Hui‐Min Xu, Shan‐Shan Zhang, Yong Li, Xing‐Huan Wang, Hong Weng (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13527044.txt.
Description
Kang-Ping Xiong, Hong Weng, and colleagues identify a detox enzyme moonlighting as a brake on prostate cancer's fat supply. Sequencing patient tumors showed GSTM4 sharply reduced, with low levels tracking higher fat content. Restoring it slowed cancer cell growth and migration and suppressed tumors and bone spread in mouse models.
The mechanism bypasses the enzyme's classic chemistry: GSTM4 grabs two partners and arranges the tagging and destruction of ACLY, the enzyme that starts fat synthesis. Starved of new lipids, tumors stalled. A clinically approved ACLY-blocking drug, bempedoic acid, also showed anti-tumor potential. The authors nominate this three-protein axis as a therapeutic target in advanced prostate cancer.
Catalog record
| CREATOR | Kang‐Ping Xiong, Fei Liu, Wang Wang, Gang Wang, Kai‐Yu Qian, Sheng Tu, Si‐Ming Chen, Hui‐Min Xu, Shan‐Shan Zhang, Yong Li, Xing‐Huan Wang, Hong Weng |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 64 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |